Back to Sites MU-JHU Care Limited CRS Site Number 5126 Address MU-JHU Care Limited CRS Upper Mulago Hill Road P.O. BOX 23491 Kampala, Uganda IMPAACT Members at this Site Teopista Nakyanzi CAB Liaison Thamali Genga CAB Member Peter Mudiima CAB Member Deo Wabwire CRS Coordinator Philippa Musoke CRS Leader Clemensia Nakabiito CRS Leader Abbey Kafumbe CRS Staff Christine Kizza CRS Staff Joyce Matovu CRS Staff Rosemary Namwanje CRS Staff Christopher Ndugwa CRS Staff Edith Oluka CRS Staff Henry Tumwijukye CRS Staff Mary Glenn Fowler CTU Principal Investigator Sue Welsch DAIDS PO Danstan Bagenda Data Manager Mike Mubiru Data Manager Winnie Nansamba Data Manager Joseph Ouma Data Manager Airene Dasal Director Charles Gabula Financial Administrator Linda Barlow-Mosha Investigator Monica Etima Investigator Brenda Kateera Investigator Kenneth Kintu Investigator Irene Lubega Investigator Mahnaz Motevalli-Oliner Investigator Nataliya Nyombi Investigator Maxensia Owor Investigator Lilian Wambuzi Investigator Eric Wobudeya Investigator Ronald Wasswa Laboratory Technician/Technologist Ali Elbireer Local Laboratory Pontiano Kaleebu Local Laboratory Isaac Ssewanayana Local Laboratory Hellen Kaganzi Medical Officer Juliane Etima N/A Judith Mbanza N/A Mark Ssenyonga Pharmacist Brenda Kakayi Pharmacist of Record Rebecca Sakwa Pharmacist of Record Enid Kabugho Protocol Coordinator Agnes Naggirinya Protocol Coordinator Dorothy Sebikari Protocol Coordinator Victoria Chou Regulatory Coordinator Joshua Kagoda Regulatory Coordinator Maria Musisi Regulatory Coordinator Paula Namayanja Regulatory Coordinator Constance Namirembe Regulatory Coordinator Neiksha Stephens Regulatory Coordinator Jim Aizire Study Coordinator Moreen Kamateeka Study Coordinator Hajira Kataike Study Coordinator Phionah Kibalama M.D. Study Coordinator Joel Maena Study Coordinator Prossy Nakanwagi Study Coordinator Joselyne Nansimbe Study Coordinator Sawsan Osman Study Coordinator Studies at this Site P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls DAIDS Number 11878 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants DAIDS Number 30020 Research Area Therapeutics Study Status Closed to Follow Up IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development Pagination Previous page Prev Page 1 Current page 2
P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls DAIDS Number 11878 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants DAIDS Number 30020 Research Area Therapeutics Study Status Closed to Follow Up
IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development